Compare ESPR & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | NVCT |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 816.9M | 721.2M |
| IPO Year | 2013 | 2021 |
| Metric | ESPR | NVCT |
|---|---|---|
| Price | $3.19 | $19.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.75 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 16.8M | 589.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $403,135,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $1.11 | $5.55 |
| 52 Week High | $4.18 | $29.28 |
| Indicator | ESPR | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 67.43 | 56.71 |
| Support Level | $3.16 | $7.05 |
| Resistance Level | $3.26 | $29.28 |
| Average True Range (ATR) | 0.02 | 1.99 |
| MACD | -0.01 | -0.58 |
| Stochastic Oscillator | 78.57 | 13.65 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.